Usage: Epclusa treats chronic hepatitis C virus (HCV) genotypes 1–6 in adults and children aged 3 and older. It is used with or without cirrhosis; patients with decompensated cirrhosis take it in combination with ribavirin.
Usage: EVOTAZ combines atazanavir (HIV-1 protease inhibitor) and cobicistat (CYP3A inhibitor) for treating HIV-1 infection in adults and pediatric patients weighing at least 35 kg, used alongside other antiretroviral agents. Treatment-experienced patients should be guided by baseline protease inhibitor resistance substitutions.
Usage: Genvoya is a complete HIV-1 treatment regimen for adults and children weighing at least 25 kg, used in treatment-naive patients or to replace current therapy in those virologically suppressed on stable antiretrovirals for at least 6 months with no treatment failure or resistance history.